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ABSTRACT
Asthma is a disease of chronic airway inflammation
that is characterized clinically by bronchial hyper-
responsiveness and airflow limitation. Chronic inflam-
mation, coupled with ongoing repair of airways
damaged by the persistent inflammatory process in
asthma, results in permanent structural and functional
airway changes (remodeling) that can lead to irre-
versible airflow obstruction. Current guidelines empha-
size treatment of the underlying inflammatory process
in asthma and recommend early, long-term anti-
inflammatory treatment to diminish or prevent the
irreversible component of airflow obstruction. Further-
more, they recognize that inhaled corticosteroids are the
most effective anti-inflammatory agents available for
the treatment of asthma. Patient adherence to pre-
scribed inhaled corticosteroid medication is associated
with decreased airway inflammation, improved pul-
monary function and symptom control. Moreover,
marked declines in morbidity and mortality due to
asthma have been attributed to appropriate use of
inhaled corticosteroids.
Strict patient adherence with prescribed anti-inflam-
matory medication is crucial for obtaining optimal
therapeutic benefit for patients with asthma. Despite
the proven effectiveness of inhaled corticosteroids,
patient adherence to prescribed therapy is often low,
resulting in increased patient morbidity. Complex
dosing regimens contribute greatly to patient non-
adherence. Thus, new once-daily regimens of inhaled
corticosteroid treatment have been introduced as
means to improve patient adherence and provide
optimal therapeutic benefit. In the present review, the
complex inflammatory and remodeling processes in
asthma and their contributions to the clinical manifes-
tations of the disease will be discussed. Currently
available, once-daily inhaled corticosteroid treatment
options and the advantages of these therapeutic
options in the treatment of persistent asthma also will
be discussed.
Key words: asthma, budesonide, inhaled cortico-
steroids, once daily, Pulmicort Respules®, Pulmicort
Turbuhaler®.
INTRODUCTION
Asthma is a chronic inflammatory disease of the airways
involving the recruitment and activation of numerous
inflammatory cell types.1,2 The underlying inflammatory
process in asthma and subsequent repair (remodeling)
result in altered structure and function of the airways,
demonstrated clinically by airway hyperresponsiveness
and airway obstruction.1,3 An irreversible component 
of airway obstruction has been associated with disease
duration and may be a direct consequence of the
ongoing remodeling process associated with uncon-
trolled chronic inflammation.4
International guidelines for the treatment of asthma
recommend early, long-term treatment with anti-inflam-
matory agents to prevent possible irreversible airflow
obstruction and recognize inhaled corticosteroids as the
most effective anti-inflammatory agents currently avail-
able for the treatment of persistent asthma.5,6 Worldwide
trends in hospital admission rates and mortality due to
asthma reflect the effectiveness of inhaled corticosteroid
therapy. A marked underuse of inhaled corticosteroids
in many countries has been associated with increasing
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morbidity and mortality due to asthma, whereas steady
declines in morbidity and mortality in other countries
have been attributed to more widespread symptom
control through the use of inhaled corticosteroids.7
Optimal therapeutic benefit from the use of inhaled
corticosteroids in asthma depends on strict adherence
to prescribed therapy. New once-daily inhaled cortico-
steroid regimens have been introduced that may increase
patient adherence to prescribed therapy and, thus,
increase therapeutic efficacy.
ASTHMA AS AN INFLAMMATORY DISEASE
Asthma is a disease of chronic airway inflammation.8
Numerous inflammatory cell types, including mast cells,
macrophages, eosinophils and lymphocytes, are involved
in the inflammatory process.1,2 These mediators of
inflammation contribute to airway hyperresponsiveness,
airflow obstruction and perpetuation of the inflammatory
process.
Mast cell and macrophage activation is the initial
response to the inciting trigger or inhaled allergen in
asthma. Activated mast cells release several pro-inflam-
matory mediators, including histamine, leukotrienes and
other lipid mediators (e.g. prostaglandins and platelet
activating factor); eosinophil and neutrophil chemotactic
factors;9 and cytokines, which include interleukin (IL)-3, 
IL-4, IL-5 and granulocyte–macrophage colony stimulat-
ing factor (GM-CSF). These cytokines, in conjunction
with IL-1 and tumor necrosis factor (TNF)-a released by
activated macrophages, up-regulate expression of endo-
thelial cell adhesion molecules and promote eosinophil
recruitment and survival.1,10 Endothelial cell adhesion
molecules, such as intercellular adhesion molecule
(ICAM)-1 and vascular cell adhesion molecule (VCAM)-1,
immobilize circulating inflammatory cells at the site of
inflammation and help to regulate their entry into the
airway mucosa.10,11
Eosinophils, the major effector cells in the inflammatory
process,1 are important for cytokine production and the
release of mediators (e.g. leukotrienes and oxygen free
radicals) and granular proteins, such as major basic
protein. Leukotrienes contribute to airway obstruction by
directly increasing airway smooth muscle tone (broncho-
constriction), mucus secretion and vascular permeability
(edema), and by affecting mucocilliary function.9 Granular
proteins, which cause damage to the airway epithelium,1,9
and sensory neuropeptides, which are released through
the actions of eosinophil-derived inflammatory mediators,
also contribute to airway hyperresponsiveness.12
T lymphocytes may be essential for persistence of
inflammation in chronic disease. Release of IL-4 (in
atopic asthma) and IL-5, predominantly by the T helper
(Th)2 subclass of T lymphocytes, contributes to IgE syn-
thesis and eosinophil production, respectively.1,10
Similar to inflammatory cells, resident bronchial
epithelial cells generate numerous cytokines, lipid media-
tors, peptides and reactive oxygen species (Table 1) that
recruit circulating inflammatory cells to the airway lumen,
modulate airway tone and regulate secretions.13,14
Inflammation associated with reduced
pulmonary function, disease severity and
bronchial hyperreactivity
Airflow limitation is the result of various inflammatory
features characteristic of asthma, including acute broncho-
constriction, airway edema and mucus plug formation
(Fig. 1).8,15 Forced expiratory volume in 1 s (FEV1), the
most critical measure of airflow limitation, usually is
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Table 1 Epithelial-derived cytokines
Chemoattractant cytokines
Colony-stimulating Pleiotropic Growth Receptors/ Lymphocyte C-X-C/a C-C/b
factors cytokines factors antagonists chemoattractant factor chemokines chemokines
GM-CSF IL-6 TGF-b Type 1 TNFR IL-16 IL-8 RANTES
G-CSF IL-11 TGF-a icIL-1Ra Type 1 GRO-a MCP-1
M-CSF IL-1 SCF GRO-g MCP-4
CSF-1 IL-10 bFGF Eotaxin
TNF-a MIP-1a (rat)
GM-CSF, granulocyte–macrophage colony stimulating factor; G-CSF, granulocyte colony stimulating factor; M-CSF, macrophage colony stimu-
lating factor; CSF, colony stimulating factor; IL, interleukin; TNF, tumor necrosis factor; TGF, transforming growth factor; SCF, stem cell factor; bFGF,
basic fibroblast growth factor; TNFR, tumor necrosis factor receptor; GRO, growth-related gene product; RANTES, regulated on activation, normal
T cell expressed and secreted; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein. Reprinted with permission from:
Polito AJ, Proud D. Epithelial cells as regulators of airway inflammation. J. Allergy Clin. Immunol. 1998; 102: 714–18.
decreased in asthma.8 Furthermore, percentage pre-
dicted FEV1 in childhood is a significant predictor of adult
pulmonary function level.16
Longitudinal studies have shown that children with fre-
quent and persistent asthma have reduced pulmonary
function in later life.16,17 A significant correlation between
asthma duration and reduced pulmonary function has been
demonstrated by Zeiger et al., using regression analysis of
data obtained from 1041 children in the Childhood Asthma
Management Program (CAMP) study. Asthma duration was
significantly (P < 0.001) associated with lower levels of
several lung functions, including percentage predicted
FEV1.18 Weiss et al. have similarly reported reduced pul-
monary function with time in a retrospective, 13-year
population-based study. The authors predicted a 5%
reduction in FEV1 by age 10 and a 7% reduction by age
15 in females who develop asthma at the age of 7.19
In a detailed comparison of the extent of inflammation
in mild intermittent and mild-to-moderate persistent
asthma, Vignola et al. have compared several markers
of inflammation in mucosal biopsies and broncho-
alveolar lavage (BAL) fluid from 24 patients with mild
intermittent asthma, 18 patients with mild-to-moderate
persistent asthma and 12 healthy control subjects.20
Mucosal biopsies demonstrated significant (P = 0.001)
increases in the numbers of activated eosinophils and 
T lymphocytes in both asthma populations, with a sig-
nificantly greater increase in patients with persistent
asthma. The BAL analysis also revealed a significantly
greater increase in eosinophil activation in persistent
asthma than in mild intermittent asthma, compared to
controls.20 These data indicate that increased disease
severity is associated with a greater degree of inflamma-
tion. Vignola et al. have also demonstrated increased
epithelial shedding in mucosal biopsy specimens from
the persistent asthma population compared with inter-
mittent and control populations. Epithelial loss, a
consequence of the inflammatory process, previously
has been associated with hyperactivity in asthma.21–23
Analysis of bronchial biopsy specimens from 11 adult
patients with atopic asthma, reported by Jeffery et al.,
has demonstrated a positive correlation between the
extent of epithelial loss and the degree of bronchial
hyperactivity.21
ONCE-DAILY INHALED CORTICOSTEROIDS IN ASTHMA 9
Fig. 1 Inflammatory features
that contribute to airflow limitation
in asthma. Reprinted with permis-
sion from Stephen T Holgate MD.15
AIRWAY REMODELING
Airway remodeling, observed in the lungs of even mildly
affected asthmatics,24,25 results from a continuous cycle of
airway damage and repair associated with chronic inflam-
mation (Fig. 2).3,26 While the process is not well defined,
release of growth factors and fibrogenic cytokines, activa-
tion of fibroblasts and myofibroblasts, increased synthesis
and deposition of collagen and increased synthesis and
release of extracellular matrix components are among the
events proposed to be involved.27 In addition, airway
epithelial cells play a prominent role by producing growth
factors and extracellular matrix proteins and influencing
fibroblast recruitment and proliferation.13 Typical patho-
logic findings of the remodeled airway wall include a
thickened bronchial subepithelial basement membrane
caused by collagen deposition24,25 and increased airway
smooth muscle mass.3 These changes in the size and com-
position of the airway wall can have a negative impact on
airway function by rendering the airways stiffer and more
prone to airflow obstruction.28 Mucous gland hyperplasia,
another feature of the remodeled airway wall,29 can
contribute further to airflow obstruction through excess
mucus production, and thickening of the airway wall can
contribute to hyperresponsiveness by amplifying the
narrowing produced by smooth muscle shortening.24,30
Irreversible airflow obstruction due to remodeling has
been reported in asthma4 and has been related to disease
severity.24,25
Current asthma treatment guidelines, which recognize
the ongoing inflammatory process in asthma and the
contribution of remodeling to irreversible loss of pul-
monary function, emphasize early and long-term
anti-inflammatory therapy.5,6 Inhaled corticosteroids are
the most potent anti-inflammatory agents available for
the treatment of asthma31 and are thus recognized as the
mainstay of treatment.5,6
The benefit of early therapeutic intervention with
inhaled corticosteroids has been supported by numerous
clinical trials in asthma.32–38 In one controlled prospective
study,32 216 children with mild-to-moderate asthma were
evaluated for 1–2 years before the initiation of treatment
with inhaled budesonide and for an additional 3–6 years
while receiving treatment. Sixty-two control subjects
who received only theophylline, b 2-agonists and sodium
cromoglycate also were evaluated over 3–7 years.
Control subjects exhibited a 1–3% annual decrease in
percentage predicted FEV1 over time, whereas subjects
receiving inhaled budesonide exhibited significant 
(P < 0.01) improvements in FEV1. Furthermore, duration
of asthma prior to inhaled corticosteroid treatment
affected patient response. Children with asthma for 2
years demonstrated significantly greater increases in FEV1
with treatment, compared with children with an asthma
duration of 5 or more years.
In a study by Haahtela et al.,33 103 newly diagnosed
adult asthmatics were randomized to receive treatment
with an inhaled corticosteroid (budesonide) or inhaled
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Fig. 2 The underlying mechanisms of asthma and its clinical evolution are shown. A cycle of chronic inflammation and ongoing
tissue remodeling culminates in disease progression and possible irreversible airflow obstruction. Reprinted with permission from
Holgate ST; The cellular and mediator basis of asthma in relation to natural history. Lancet 1997; 350 (Suppl. 11): 5–9.26
terbutaline for 2 years. In a follow-up study,34 patients
who received budesonide for the first 2 years were ran-
domized to either continue inhaled corticosteroid
treatment or to receive placebo. Patients who received
terbutaline for the first 2 years were crossed over to treat-
ment with budesonide. After 1 year of treatment, those
patients treated with budesonide from the onset of diag-
nosis demonstrated greater improvements in pulmonary
function and decreased bronchial hyperreactivity com-
pared with patients initially receiving terbutaline. These
studies stress the importance of early intervention, before
the onset of irreversible airflow obstruction, to achieve
optimal therapeutic response. The study by Haahtela
et al. has also demonstrated the importance of continu-
ing inhaled corticosteroid therapy, because pulmonary
function deteriorated in 67% of patients who were
switched from budesonide to placebo.
NEW REGIMEN OF ONCE-DAILY INHALED
CORTICOSTEROIDS FOR ASTHMA
Poor adherence with prescribed therapeutic regimens
is common in patients with chronic disease39 and is an
important factor in the failure to respond to prescribed
therapy.40 Numerous reports have documented poor
adherence with medication in patients with asthma and
chronic obstructive pulmonary disease.41–45 In a study on
adherence in a general practice setting, Dekker et al.
have investigated adherence with prescribed cromogly-
cates, b 2-agonists, anticholinergics and theophyllines,
corticosteroids and other pulmonary medications in 156
patients between 12 and 64 years of age. Adherence,
defined as a reported daily intake of ‡ 50% of the pre-
scribed amount of medication, was demonstrated in only
30% of patients overall and 58% of patients with daily
symptoms.43 Adherence to a once-daily dosing schedule
was reportedly higher than that with multiple-daily dosing
schedules.43 Electronic monitoring of inhaler devices has
been used in several studies to objectively monitor patient
adherence with prescribed anti-asthma medica-
tions.41,42,45 Results of these studies have demonstrated
poor patient adherence, with both underuse and overuse
of prescribed medications. In one such study, only one of
34 patients enrolled in either a 12-week clinical trial with
four daily doses of a prescribed cromolyn-like agent
(Lodoxamide) or a 28-day trial with four daily doses of a
prescribed corticosteroid (tixocortal pivalate) was consid-
ered adherent. A patient was considered adherent if
appropriate medication was used on ‡ 75% of days
studied; in both trials, patients took the study drug as pre-
scribed on a mean of approximately 37% (range 0–77%)
of days.45
Non-adherence with prescribed therapy has been asso-
ciated with increased morbidity in both pediatric and adult
asthmatics.41,44 Bender et al. have reported an association
between marked underuse of prescribed daily inhaled
corticosteroid medication and treatment failure, urgent-
care contact with a clinician and administration of
systemic corticosteroids in 24 asthmatic children during
a 3-month study period.41 Moreover, Horn et al. have
demonstrated an association between patient adherence
with a standard, incremental regimen of inhaled salbuta-
mol and decreased morbidity in a 9-month study of 160
adult asthmatics.44 Urine salbutamol concentrations, used
as a measure of patient adherence, increased with the
incremental doses prescribed in patients with significantly
improved FEV1. Both FEV1 and peak expiratory flow rate
(PEFR) deteriorated in those patients showing no increase
in urine salbutamol concentration over the study period.
These studies demonstrate a significant lack of adherence
to prescribed medications in patients with asthma and
further demonstrate that poor adherence is a cause of
increased patient morbidity.
Complex dosing regimens have a negative impact on
patient adherence with prescribed therapeutic regimens 
in asthma and other chronic diseases.40 Eisen et al. have
suggested that selecting medications that permit the
lowest daily prescribed dose frequency may, in fact, 
be the single most important strategy to improve
patient adherence.46 Numerous studies have shown
that patient adherence increases as drug-dosage 
frequency decreases46–49 and improved adherence with
inhaled corticosteroid therapy in asthma has been
demonstrated with reduced daily dose frequencies.50 In 
a study comparing patient adherence to schedules of 
two and four daily doses with the inhaled corticosteroid 
flunisolide, a significant (P<0.001) increase in non-
adherence was observed in patients switched from four
inhalations twice daily to two inhalations four times daily.
The percentage of days in which patients were non-
adherent rose from 20.2 – 40.3 with twice-daily dosing
to 57.1 – 49.6 with four times daily dosing.50
Patient preference for once-daily dosing of inhaled
corticosteroid therapy in asthma has been reported in a
trial assessing the efficacy of budesonide dry powder
administered via Turbuhaler® in 141 patients (‡ 12 years
of age) with mild asthma. Ninety-seven percent of pa-
tients enrolled in the study preferred once-daily dosing.51
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Furthermore, using a decision-analysis approach to
evaluating once-daily versus twice-daily dosing of theo-
phylline, Jordan and Reichman have considered the
effects of patient non-adherence on therapeutic efficacy.
These authors have suggested that anticipated gains in
efficacy obtained with multiple daily dosing might be
eliminated by lower patient adherence and conclude that
once-daily dosing is favorable to twice-daily dosing for
most patients.52
In addition to improving patient adherence, once-daily
administration of inhaled corticosteroids may reduce the
potential for adverse systemic effects. In an assessment
of the systemic effects of single and multiple doses of
inhaled fluticasone propionate and inhaled budesonide
in healthy volunteers, Lönnebo et al. have demonstrated
increased systemic effects (i.e. changes in plasma cortisol
and white blood cell counts) with multiple versus single
drug doses.53 Systemic accumulation, which is greater for
those inhaled corticosteroids exhibiting a longer elimina-
tion half-life (e.g. fluticasone propionate), may explain
the presence of increased systemic effects;54 infrequent
dosing regimens may reduce systemic accumulation and
thus decrease the long-term risk for adverse effects.
ONCE-DAILY BUDESONIDE INHALATION
POWDER (PULMICORT TURBUHALER®) IN THE
TREATMENT OF ASTHMA
Pulmicort Turbuhaler® (AstraZeneca, Wayne, PA, USA) is a
dry powder inhaler that differs from conventional pressur-
ized metered-dose inhalers (pMDI) in that it is breath
actuated and optimal drug delivery does not rely on the
coordination of inhaler actuation with inspiration. Because
failure to properly coordinate actuation with inspiration has
been reported as a frequent error in inhaler technique,
regardless of age,55 dry powder inhalers may improve drug
delivery and increase therapeutic efficacy compared to
conventional pMDI, in both adult and pediatric asthma
patients.
Patient preference for Turbuhaler® over pMDI has been
reported in two separate studies.56,57 In a 10-week open-
label, randomized, crossover study comparing the safety
and efficacy of budesonide administered via pMDI
with spacer to that of budesonide administered via
Turbuhaler® in 28 patients with stable asthma, patient
preference was assessed by questionnaire at the end
of the study period. Turbuhaler® was rated significantly
better than pMDI in every aspect addressed in the prefer-
ence questionnaire, including general preference, ease
of inhalation, size of the device, taste, cough, hoarseness
and other local irritation.56 In a second multicenter, open-
label, crossover study, inhalation device preferences were
determined in 123 adult patients with stable asthma.57
Patient preferences for administration of terbutaline
(via pMDI or Turbuhaler®) and budesonide (via pMDI with
Nebuhaler or Turbuhaler®) were determined by question-
naire following 14-day treatment periods with each
inhalation device. Turbuhaler® was rated significantly
(P < 0.001) higher than pMDI (for terbutaline) and pMDI
with Nebuhaler (for budesonide).
Clinical trials have demonstrated greater efficacy of
budesonide inhalation powder when administered via
Turbuhaler® compared with pMDI.56,58 In a randomized,
double-blind, parallel-group study conducted in 126
children with persistent asthma, Agertoft and Pedersen
compared the effects of budesonide administered via
Nebuhaler with those of half the dose of budesonide
administered via Turbuhaler®.58 To ensure that patients
were not being overtreated prior to enrolment, their
normal doses of budesonide administered via Nebuhaler
were reduced by half; only those patients demonstrating
deterioration in asthma control at the reduced doses were
enrolled in the study. Following stabilization and a 2-
week run-in period, patients were randomized to receive
budesonide via Nebuhaler at their normal dose or via
Turbuhaler® at half their normal dose for 9 weeks. Other
than reduced b 2-agonist use in the Turbuhaler® group, no
differences in effect were demonstrated between treatment
via Nebuhaler and treatment at half the dose of budes-
onide via Turbuhaler®, indicating increased efficacy of
budesonide via Turbuhaler®. A second open-label, ran-
domized, crossover study conducted in 28 patients with
stable asthma has similarly demonstrated that budesonide
via Turbuhaler® was at least as effective as budesonide via
pMDI at daily doses of 800 and 1600 m g.59
The demonstration of equivalent efficacy at half the dose
of budesonide administered via Turbuhaler® compared
with pMDI, by Agertoft and Pedersen, confirmed previous
reports of greater lung deposition of inhaled medication
with Turbuhaler®.59,60 Lung depositions of budesonide and
terbutaline administered via Turbuhaler® are reportedly
twice those following administration via pMDI. These data
suggest that the same degree of asthma control can be
achieved at a lower dose using Turbuhaler®, reducing the
potential risk for adverse systemic effects.
Numerous trials have demonstrated the safety and
efficacy of once-daily budesonide administered via
Turbuhaler® in children and adults with persistent asthma
12 J LEFLEIN
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(Table 2) and have further demonstrated equivalent effi-
cacy of once-daily versus twice-daily administration.61–63
Both Campbell et al.61 and Jones et al.63 have reported
equivalent efficacy of budesonide 400 m g administered
once daily via Turbuhaler® and 200 m g administered
twice daily in the treatment of children from 5 to 12 years
of age with mild asthma and in the treatment of patients
from 12 to 70 years of age with mild-to-moderate
asthma, respectively. Similarly, Chisholm et al.62 have
reported that 200 m g budesonide administered once daily
via Turbuhaler® is as effective as 100 m g given twice daily
in a randomized, double-blind, parallel-group study con-
ducted in 76 adult asthmatics with mild-to-moderate
disease severity. These studies support the efficacy of
budesonide administered via Turbuhaler® in the treatment
of persistent asthma in children and adults and further
support the use of once-daily dosing regimens for the
treatment of patients with mild-to-moderate asthma.
ONCE-DAILY BUDESONIDE INHALATION
SUSPENSION (PULMICORT RESPULES®) IN THE
TREATMENT OF ASTHMA
Difficulties encountered in using conventional inhalation
devices by young children and by caregivers in adminis-
tering therapy to infants and young children may result 
in suboptimal drug delivery and reduced therapeutic
efficacy.64 Budesonide inhalation suspension is the first
nebulized corticosteroid developed for pediatric asthma
patients and is the first inhaled corticosteroid developed
for use in children <4 years of age. It is now available
commercially in 35 countries. For infants and very young
children who lack the coordination and knowledge
to properly use other delivery devices, nebulization is
the delivery method of choice.65,66 Clinical trials have
demonstrated the safety and efficacy of once-daily
budesonide inhalation suspension in children with mild-
to-moderate persistent asthma (Table 3).
OTHER ONCE-DAILY INHALED CORTICOSTEROID
REGIMENS
Whereas substantial evidence supports the safety and
efficacy of once-daily administration of Pulmicort® in the
treatment of pediatric and adult asthmatics, data sup-
porting the safety and efficacy of other once-daily inhaled
corticosteroid regimens are limited.67,68 Only one study
has been published on once-daily dosing of inhaled
flunisolide, which was as effective as twice-daily dosing in
366 asthmatics (6–70 years of age) with well-controlled
disease. Patients switched from two inhalations of flu-
nisolide twice daily to four inhalations once daily of an
equivalent dose (1000 m g) demonstrated similar changes
in pulmonary function, asthma symptoms, and b -agonist
use.68 Similarly, only one comparative study of the safety
and efficacy of once- or twice-daily administration of
inhaled beclomethasone has demonstrated no significant
differences in the control of asthma, based on pulmonary
function tests, asthma symptoms and bronchodilator use,
in 37 adults with moderate asthma.67
In conclusion, current asthma treatment guidelines,
which are based on knowledge of the underlying inflam-
matory process in asthma and evidence that chronic
inflammation leads to irreversible changes in airway
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Table 3 Published studies supporting the efficacy of once-daily budesonide inhalation suspension
Author Patient Age range Disease
(year) Dose number (years) severity Conclusions
Baker et al.74 0.25 mg QD 480 0.5–8 Moderate Results suggest that 0.50 mg is minimal 
(1999) 1.0 mg QD effective dose; however, significant 
0.25 mg BID improvments in evening PEF and
0.50 mg BID bronchodilator use with 0.25 mg QD
compared to PBO. QD dosing efficacious 
relative to PBO.
Kemp et al.75 0.25 mg QD 359 0.5–8 Mild Significant improvements in asthma symptoms 
(1999) 0.50 mg QD and bronchodilator use with all doses and in 
1.0 mg QD FEV1 with 0.50 mg and 1.0 mg QD, 
compared to PBO.
BID, twice daily; FEV1, forced expiratory volume in 1 s; PBO, placebo; PEF, peak expiratory flow; QD, once daily. Both studies were randomized,
double-blind, placebo-controlled, parallel-group studies of 12 weeks duration.
structure and function, emphasize early and long-term
anti-inflammatory treatment to diminish the irreversible
component of airway obstruction.5,6 Inhaled cortico-
steroids are the most effective anti-inflammatory agents
available for the treatment of asthma and their use 
is associated with decreased airway inflammation,
improved pulmonary function and symptom control.
Poor patient adherence to prescribed therapy has been
associated with increased morbidity in asthma41,44 and
evidence suggests that simple dosing regimens increase
patient adherence.46 New once-daily inhaled cortico-
steroid regimens for the treatment of asthma may
improve patient adherence to prescribed medications
and thereby optimize therapeutic efficacy.
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